Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 911,774 shares of the medical equipment provider’s stock after purchasing an additional 72,326 shares during the period. Thrivent Financial for Lutherans’ holdings in Zimmer Biomet were worth $83,163,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Monarch Capital Management Inc. raised its holdings in Zimmer Biomet by 2.0% during the 2nd quarter. Monarch Capital Management Inc. now owns 35,028 shares of the medical equipment provider’s stock worth $3,201,000 after buying an additional 695 shares during the period. State of Wyoming purchased a new position in shares of Zimmer Biomet in the second quarter worth approximately $124,000. CYBER HORNET ETFs LLC acquired a new stake in shares of Zimmer Biomet during the second quarter valued at approximately $50,000. FORA Capital LLC purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $2,307,000. Finally, Headlands Technologies LLC acquired a new position in Zimmer Biomet in the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the topic of several recent analyst reports. BTIG Research cut their target price on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Royal Bank Of Canada reduced their price objective on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Johnson Rice set a $112.00 target price on Zimmer Biomet in a research note on Wednesday, November 5th. Rothschild & Co Redburn started coverage on shares of Zimmer Biomet in a research report on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target for the company. Finally, Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and an average target price of $108.25.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $91.60 on Monday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $85.33 and a fifty-two week high of $114.44. The stock’s 50-day moving average is $95.64 and its two-hundred day moving average is $96.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. The firm has a market cap of $18.15 billion, a P/E ratio of 22.67, a PEG ratio of 2.41 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter in the previous year, the business posted $1.74 EPS. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.